[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE
trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide
therapeutic decision making for functional precision oncology trials. The unique ability of
FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may
improve confidence among research oncologists that an ER+ metastatic breast cancer patient is
truly refractory to hormonal therapies which is a critical determination in the study design
of the FORESEE trial.